8-K: RAPT Therapeutics Reports Q3 2025 Results, Advances Pipeline

RAPT Therapeutics announced its third quarter 2025 financial results, highlighted by positive Phase 2 CSU data, initiation of a Phase 2b food allergy trial, and a $250 million public offering.

Summary

• Initiated the prestIgE Phase 2b trial of ozureprubart (RPT904) in food allergy following FDA IND clearance in September.
• Announced positive topline data from the Phase 2 trial of ozureprubart as monotherapy in chronic spontaneous urticaria (CSU), showing comparable efficacy and safety to omalizumab at Q8W and Q12W dosing compared to omalizumab Q4W.
• Completed an underwritten public offering in October 2025, raising gross proceeds of $250 million and net proceeds of approximately $234.4 million.
• The recent financing is projected to fund operations to mid-2028, including the planned initiation of Phase 3 studies of ozureprubart in CSU.
• Net loss for the third quarter of 2025 was $17.6 million, an improvement from $18.4 million for the third quarter of 2024.
• Net loss for the nine months ended September 30, 2025, was $52.4 million, an improvement from $76.6 million for the same period in 2024.
• Research and development expenses decreased to $12.0 million for Q3 2025 (from $13.3 million in Q3 2024) and to $36.4 million for the nine months ended September 30, 2025 (from $60.8 million in the same period 2024).
• General and administrative expenses increased to $7.3 million for Q3 2025 (from $6.4 million in Q3 2024) and to $21.8 million for the nine months ended September 30, 2025 (from $20.9 million in the same period 2024).
• Cash and cash equivalents and marketable securities totaled $157.3 million as of September 30, 2025, prior to the October public offering proceeds.

Sentiment

Score: 8

Explanation: The filing reports positive clinical trial data for a key pipeline asset, successful capital raise extending the cash runway, and improved financial losses, all of which are strong positive indicators for a clinical-stage biopharmaceutical company.

Positives

• Positive topline data from the Phase 2 trial of ozureprubart in CSU, demonstrating comparable efficacy and safety to omalizumab at less frequent dosing (Q8W and Q12W vs. Q4W).
• Initiation of the prestIgE Phase 2b trial of ozureprubart in food allergy, expanding the clinical pipeline into another large IgE-driven indication.
• Successful completion of a $250 million public offering, significantly strengthening the balance sheet.
• Extended cash runway to mid-2028, providing capital for planned Phase 3 studies in CSU.
• Reduced net loss for both the third quarter ($17.6 million vs. $18.4 million year-over-year) and the nine-month period ($52.4 million vs. $76.6 million year-over-year).
• Significant decrease in research and development expenses for both the quarter and nine-month periods compared to the prior year.

Negatives

• Continued net losses, totaling $17.6 million for Q3 2025 and $52.4 million for the nine months ended September 30, 2025.
• Increased general and administrative expenses for both the third quarter and nine-month periods compared to the prior year.

Risks

• Unexpected or unfavorable safety or efficacy data observed during clinical studies.
• Preliminary data and trends may not be predictive of future data or results or may not demonstrate safety or efficacy or lead to regulatory approval.
• Reliance on partners and other third parties for development and commercialization.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including ongoing overseas conflicts, tariffs, trade tensions, fluctuations in inflation and interest rates, and other economic uncertainty).
• Changes in expected or existing competition.
• Changes in the regulatory environment.
• Uncertainties and timing of the regulatory approval process.
• Sufficiency of cash resources, despite the recent capital raise, for long-term program advancement.

Future Outlook

RAPT Therapeutics plans to report topline results from Jeyou's Phase 2 trial of ozureprubart in asthma and provide additional details from the recently reported Phase 2 clinical trial in CSU at a medical meeting next year. The company also intends to meet with the FDA and other regulatory agencies to discuss the registrational pathway for ozureprubart in CSU, with planned initiation of Phase 3 studies. The current cash balance is projected to fund operations to mid-2028.

Management Comments

• "We have considerable momentum heading into the end of the year."
• "We see tremendous potential for ozureprubart in large IgE-driven indications such as food allergy and CSU, and our recent financing gives us additional capital to advance our programs."

Industry Context

RAPT Therapeutics operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on immunology. The positive Phase 2 data for ozureprubart in CSU, demonstrating comparable efficacy to omalizumab (a well-established biologic), positions it as a significant potential competitor in the IgE-driven inflammatory disease market. The initiation of a Phase 2b food allergy trial further diversifies its pipeline into another large market with unmet needs. The successful capital raise is critical for funding the expensive late-stage clinical development required in this industry.

Comparison to Industry Standards

• Ozureprubart at both Q8W and Q12W dosing demonstrated comparable efficacy and safety to omalizumab at Q4W dosing in the Phase 2 CSU trial.
• The data from both ozureprubart Q8W and Q12W treatment arms showed numerically greater improvement on the UAS7 endpoint and numerically higher proportion of patients with UAS7=0 at all timepoints (Weeks 8, 12 and 16) compared to omalizumab Q4W.
• Omalizumab (marketed as Xolair by Genentech and Novartis) is a leading biologic therapy for CSU, asthma, and other allergic conditions, setting a high benchmark for new treatments.

Stakeholder Impact

• Shareholders: Positive impact due to strengthened balance sheet, extended cash runway, positive clinical data, and advancement of pipeline, potentially increasing long-term value.
• Employees: Continued employment and potential for growth as programs advance towards late-stage development.
• Customers (future patients): Potential for new, effective therapies for food allergy and CSU, addressing significant unmet medical needs.
• Creditors: Improved financial stability and extended cash runway reduce credit risk.
• Partners (Jeyou): Continued collaboration and potential for shared success in advancing ozureprubart.

Next Steps

• Report topline results from Jeyou's Phase 2 trial of ozureprubart in asthma.
• Provide additional details from the recently reported Phase 2 clinical trial in CSU at a medical meeting next year.
• Meet with the FDA and other regulatory agencies to discuss the registrational pathway in CSU.
• Initiate Phase 3 studies of ozureprubart in CSU.

Key Dates

Recommendation

The positive Phase 2 data for ozureprubart in CSU, demonstrating comparable efficacy to an established market leader (omalizumab) with potentially less frequent dosing, is a significant de-risking event for the company's lead asset. The successful $250 million capital raise provides a substantial cash runway to mid-2028, funding critical Phase 3 development. While still a clinical-stage company with inherent risks, these developments significantly enhance the company's valuation proposition and future commercial potential in large, unmet medical need markets like CSU and food allergy. The reduced net loss also indicates improving financial management, making this a compelling investment opportunity.

Keywords

RAPT Therapeutics, ozureprubart, RPT904, food allergy, chronic spontaneous urticaria, CSU, asthma, immunology, biopharmaceutical, clinical trial, Phase 2, Phase 3, public offering, financial results, IgE-driven diseases, omalizumab